Presentation is loading. Please wait.

Presentation is loading. Please wait.

Diabetes Update: Michael Gottschalk, M.D, Ph.D.

Similar presentations


Presentation on theme: "Diabetes Update: Michael Gottschalk, M.D, Ph.D."— Presentation transcript:

1 Diabetes Update: Michael Gottschalk, M.D, Ph.D.
Department of Pediatrics University of California, San Diego

2 Diabetes Mellitus Type 1 70-80 % Type 2 20-25% MODY 1-2% Autoimmune
Insulin resistance Insulin deficiency MODY % Monogenic disorder

3 Type 1 Diabetes Mellitus
Autoimmune Disease

4 Chromosome 6 High risk genotype HLA complex Regulate immune response
HLA-DR3, HLA-DR 4, HLA-DR3/4

5 Etiology of Type 1 Diabetes Mellitus
Genetics Risk of developing T1DM Environment Trigger for developing T1DM

6

7 T1D incidence is rising 3-5% per year

8

9 Normal Skin Acanthosis Nigricans Hyperkeratosis Papillomatosis

10

11 Maturity Onset Diabetes of the Young (MODY)

12 Diabetes Medical Management Plan
Diabetes in School Diabetes Medical Management Plan Insulin Meals Exercise Hypoglycemia Hyperglycemia Ketone testing

13 Insulin Products Regular Insulin Analogue Insulin NPH Insulin
Glulisine (Apidra®) Lispro (Humalog®) Aspart (Novolog®) NPH Insulin Combination Novolog® Mix 70/30 Humalog® Mix 75/25 Novolin® 70/30 Long-Acting Insulin Glargine (Lantus®) Determir (Levemir®)

14

15 Insulin Preparations Regular Insulin

16 Insulin Preparations Regular Insulin Analog Insulin

17

18 Analog Insulin

19 Insulin Preparations NPH

20

21

22 Glargine (Lantus®)

23 Glargine (Lantus®)

24 Intra-subject Variability Insulin Glargine
32 24 16 8 32 24 16 8 Subject 14 Subject 18 Subject 19 Subject 22 Concentrations [mlU/mL] 32 24 16 8 Subject 27 Subject 28 Subject 34 Subject 35 PK/PD of Insulin Glargine Intra-Subject Variability of Action This slide shows insulin glargine activity after two injections (7-day washout period between injections) in 12 healthy male subjects (Study 1012). Time [h] Visit 2 Visit 3 Scholtz et al. Diabetes 1999;48(suppl 1):A97. Abst 416; Study 1012

25 Levemir

26 Insulin Variability Preparation Size of the Injection
Injection Technique Injection Site Subcutaneous blood flow

27 Insulin Levels After NPH Injection
Child Adolescent Adult Insulin Level Elapsed time (hours)

28 Size of the Injection Larger size of the dose
Variability in absorption is increased Total amount absorbed is decreased

29 Injection Technique

30 Site of injection Abdomen is fastest Arm is intermediate
Legs and buttock are the slowest

31 Increased Subcutaneous Blood Flow

32 What Does Insulin Do?

33 Normal glucose metabolism
+ Skeletal Muscle Liver Glucose + Fat Pancreas Insulin Glucose and other nutrients GI Tract Adapted from Cell, Vol 97, 9-12

34 Normal glucose metabolism Fasting
Brain Ketone bodies + Free fatty acids + Skeletal Muscle Liver Fat Glucose Pancreas Adapted from Cell, Vol 97, 9-12

35 Normal glucose metabolism
Brain Ketone bodies Amino acids Triglyceride + Free fatty acids Skeletal Muscle Liver Glucose + Fat Pancreas Insulin Glucose and other nutrients GI Tract Adapted from Cell, Vol 97, 9-12

36 Insulin BASAL AND BOLUS
Regulate hepatic glucose production Prevent ketone production Equivalent to ~ ½ of daily insulin requirement Bolus: Prevent postprandial hyperglycemia

37 Insulin Regimens

38 2 injections per day Regular and NPH Reg/NPH Reg/NPH B sn L sn D sn

39 3 injections per day Analog and Lantus B L D

40 3 injections per day Analog and Lantus Analog Analog Analog Lantus
B L D

41 2 injections per day Humalog/Novolog, Lantus and NPN
Analog Analog NPH Lantus B L D

42 Insulin Pens

43 Insulin Pumps Subcutaneous Insulin Infusion (SCII)

44 Insulin Pump with Analog Insulin B L D

45 Insulin Pump Therapy

46 CSII vs MDI Lower HbA1c Lower prevalence of severe hypoglycemia
0.5% improvement Lower prevalence of severe hypoglycemia 60-70% reduction Less glucose variability

47 Exercise and Glucose Normal glucose (70 – 120) “The Goal”
Hypoglycemia (Low glucose) Lack of carbohydrate Insulin excess Increased insulin sensitivity Muscle glucose uptake independent of insulin Hyperglycemia (High glucose) Excess carbohydrate Insulin deficiency Stress/Nervousness

48 Exercise Intensity Moderate - Sustained High - Short Duration Aerobic
Tend to cause low glucose Activities: Running Cycling Swimming Soccer High - Short Duration Anaerobic Tend to cause high glucose Activities: Sprinting Power lifting Hockey

49 100 40 200 Insulin Adrenaline Cortisol Growth Hormone Glucagon

50 Exercise 100 40 200 Adrenaline Insulin Cortisol Glucagon
Growth Hormone Glucagon

51 Glucose Monitoring

52 Interstitial Glucose

53 Continuous Glucose Sensors
Guardian Navigator Dexcom

54

55

56 Type 2 DM Pathophysiology

57 Type 2 DM Treatment

58

59 Where Should Diabetes Care Be Provided?
Diabetes care should be provided wherever your child is on campus, on the school bus, and at off-campus activities. If the parent requests it and the treating physician authorizes it, the child will be permitted to check his or her blood glucose level and to otherwise provide diabetes self-care in the: classroom, in any area of the school or school grounds, during any school-related activity, upon specific request by the parent, in a private location


Download ppt "Diabetes Update: Michael Gottschalk, M.D, Ph.D."

Similar presentations


Ads by Google